- $156.05m
- $102.51m
- $42.17m
Coherus Oncology Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Coherus BioSciences Q2 Adjusted EPS USD 116077710
Coherus Oncology Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Coherus Completes Strategic Transformation To Coherus Oncology
Coherus BioSciences Inc reports results for the quarter ended March 31 - Earnings Summary
Coherus BioSciences Inc expected to post a loss of 21 cents a share - Earnings Preview
Coherus BioSciences Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Coherus Completes Strategic Transformation With Successful Divestiture Of Udenyca Franchise
Brief: Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio
Coherus BioSciences Inc reports results for the quarter ended December 31 - Earnings Summary
Coherus BioSciences Inc expected to post a loss of 13 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-PSQ Holdings, Core Scientific, Keros
U.S. STOCKS ON THE MOVE-BlackRock, Terns Pharma, PSQ Holdings
U.S. STOCKS ON THE MOVE-Citi Trends, PG&E, BlackRock
Coherus Bio jumps on deal to divest biosimilar of Amgen's Neulasta
Coherus BioSciences Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Coherus BioSciences Q3 Operating Income USD -6.387 Million Vs. IBES Estimate USD -13.3 Million
Coherus BioSciences Inc expected to post a loss of 12 cents a share - Earnings Preview
Coherus BioSciences Inc expected to post a loss of 12 cents a share - Earnings Preview